Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dahae Hong"'
Autor:
Jongmin Yoon, Don-Gil Lee, Haengjin Song, Dahae Hong, Ji Soo Park, Changhee Hong, Kyung Mi An, Jung Woo Lee, Joon-Tae Park, Hongchul Yoon, Jihoon Tak, Sang Geon Kim
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 117044- (2024)
Xelaglifam, developed as a GPR40/FFAR1 agonist, induces glucose-dependent insulin secretion and reduces circulating glucose levels for Type 2 diabetes treatment. This study investigated the effects of Xelaglifam in comparison with Fasiglifam on the i
Externí odkaz:
https://doaj.org/article/ba1ea162fd884b25ab82e6eb1a5aff1e
Autor:
Jong-Hee Ko, Hyuk-Sang Kwon, Bomin Kim, Gihong Min, Chorong Shin, Seok-Woo Yang, Seong Wook Lee, Youngmin Lee, Dahae Hong, Yong-Sung Kim
Publikováno v:
Biomolecules, Vol 10, Iss 6, p 919 (2020)
Although bevacizumab (Avastin®) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simul
Externí odkaz:
https://doaj.org/article/d734c11c4d374bd095a4f1a1a34a1d76
Autor:
Haengjin Song, Chorong Shin, Hyun-Jung Kwak, Jongmin Yoon, Hyo-Jung Song, Eunhye Jang, Kyungmi An, In-Gyu Je, Don-Gil Lee, Jung Ho Kim, Seolhee Lee, Dahae Hong, Jisu Kim, Chang-Hee Hong, Yearin Jun
Publikováno v:
Diabetes. 70
G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1), a clinically validated anti-diabetes target, enhances insulin secretion in type 2 diabetes. It is known that the effect of glucose-stimulated insulin secretion (GSIS) in pancreatic β cells is mediate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a69e891cae97c17e3dcdf5a4430904d7
https://doi.org/10.2337/db21-122-lb
https://doi.org/10.2337/db21-122-lb
Autor:
A-Rang Im, Yearin Jun, Jae Eui Shin, Yeongran Yoo, Sohn Te-Ik, Kyungmi An, Chang Min Whan, Jung Ho Kim, Jung-Eun Park, Woojin Jeon, Dahae Hong, Chang-Hee Hong, Eunhye Jang, In-Gyu Je
Publikováno v:
Diabetes. 70
GLP-1R agonists comprise a growing class of agents that deliver unprecedented efficacy in the treatment of diabetes. We discovered promising compounds for the development of a novel small molecule GLP-1R agonist and examined their efficacy in cynomol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248565308fc159527eb37f15be71369e
https://doi.org/10.2337/db21-644-p
https://doi.org/10.2337/db21-644-p
Autor:
In-Gyu Je, Seolhee Lee, Eunhye Jang, Jongmin Yoon, Kyungmi An, Yearin Jun, Don-Gil Lee, Haengjin Song, Hyun-Jung Kwak, Hyo-Jung Song, Dahae Hong, Jisu Kim, Jung Ho Kim, Chang-Hee Hong, Chorong Shin
Publikováno v:
Diabetes. 70
GPR40 has been considered a potential therapeutic target for type 2 diabetes because activation of GPR40 stimulates insulin secretion when glucose levels increased. Fasiglifam, a GPR40 agonist, was withdrawn from clinical development in Phase III due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5039027e87583ae398fb5cba3d8016cd
https://doi.org/10.2337/db21-124-lb
https://doi.org/10.2337/db21-124-lb
Autor:
Chorong Shin, Yearin Jun, Hyun-Jung Kwak, Jongmin Yoon, Seolhee Lee, In-Gyu Je, Eunhye Jang, Haengjin Song, Jung Ho Kim, Chang-Hee Hong, Dahae Hong, Jisu Kim, Hyo-Jung Song, Kyungmi An, Don-Gil Lee
Publikováno v:
Diabetes. 70
GPR40/FFAR1 is a G-protein-coupled receptor predominantly expressed in pancreatic β-cells. GPR40 agonists are known to stimulate insulin secretion and reduce circulating glucose levels in a glucose-dependent manner. Currently, IDG-16177, as a GPR40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3af04e0a0eaea2e801459ad5d987486e
https://doi.org/10.2337/db21-123-lb
https://doi.org/10.2337/db21-123-lb
Publikováno v:
Finance Research Letters. 28:355-362
Using the Korean stock market data between 2000 and 2017, this paper examines the order imbalances of different investors around monetary policy announcements. In line with the temporary reallocation of risk hypothesis, individual investors sell sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f492b24a61f04168a2b91f58940176af
https://doi.org/10.1016/j.frl.2018.06.008
https://doi.org/10.1016/j.frl.2018.06.008
Autor:
Jong Min Yoon, In-Gyu Je, Myong-Jae Lee, Don-Gil Lee, Kyung Mi An, Hyun-Jung Kwak, Chang-Hee Hong, Do-Hee Kim, Dahae Hong, Hyo-Jung Song
Publikováno v:
Diabetes. 69
GPR40/FFAR1 is a G-protein-coupled receptor predominantly expressed in pancreatic β-cells. GPR40 agonists are known to stimulate insulin secretion and reduce circulating glucose levels in a glucose-dependent manner. We investigated IDG-16177(ID11014
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b5ed67eff0926d5add5f832d5ce5cab
https://doi.org/10.2337/db20-118-lb
https://doi.org/10.2337/db20-118-lb
Autor:
Jae-Hoon Kang, Joon-Tae Park, Jeongcheol Shin, Soo Y. Ko, Kyung-Mi An, Jeong-Ah Kim, Soobong Park, Do-Hee Kim, Dahae Hong, Jongmin Yoon, Hyun-Jung Kwak, Hyo-Jung Song, Hong-Sub Lee, Ji-hun Yang, Dong-Gu Jeong, An-Na Moon, Myong-Jae Lee, Chang-Hee Hong, Shuolin Cui
Publikováno v:
Bulletin of the Korean Chemical Society. 38:838-844
GPR40 is one of the most prominent targets for the treatment of type 2 diabetes (T2DM), and has its role in insulin secretion via blood-glucose-dependent manner with a minimum risk of hypoglycemia. In order to discover novel antidiabetics bearing the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64ecf33fc7fe7ac9c9d0006070daccbb
https://doi.org/10.1002/bkcs.11178
https://doi.org/10.1002/bkcs.11178
Autor:
Hyuk-Sang Kwon, Dahae Hong, Seok-Woo Yang, Chorong Shin, Gihong Min, Youngmin Lee, Yong Sung Kim, Bomin Kim, Jong-Hee Ko, Seong Wook Lee
Publikováno v:
Biomolecules
Volume 10
Issue 6
Biomolecules, Vol 10, Iss 919, p 919 (2020)
Volume 10
Issue 6
Biomolecules, Vol 10, Iss 919, p 919 (2020)
Although bevacizumab (Avastin®
) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefor
) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b95416e85f54443721276c8d44b3767
https://doi.org/10.3390/biom10060919
https://doi.org/10.3390/biom10060919